The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
there were a handful of cases where in the process of screening for tromis they're discovering not that the mother has additional chromosomes that can be attributed to the fetus but she has significant mutations across a number of genes that also are probably showing up in relatively small amounts because they're not in all of her cells
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
so this is one of the the things that kind of contributed to the to the uh evidence that cancer screening uh might be possible using self- fre DNA which is these incidental findings as I mentioned earlier you know we already knew that yes tumors do put self- pre DNA um into the blood string but this was a profound demonstration that um uh you know in in ual clinical practice you could find undiagnosed Cancers in asymptomatic individuals um and that it was highly specific meaning that when when it was found using this method um you know it it almost well I think in those initial ones it was every case but almost every case turned out to have cancer
Meredith and and Daria they published a paper in Jam which um for anyone interested which details these um 10 or so cases um and what happened and in each of them it was a mix um I think there was a neuroendocrine um uterine some GI cancers um it was a smattering of different things
Whole-body MRI screening in healthy adults produces more incidentaloma harm than cancer-mortality benefit.
Starting colonoscopy screening at 45 (vs 50) prevents enough early-onset cancers to justify the population cost.
Multi-cancer liquid-biopsy tests like Galleri detect early cancers at a stage that meaningfully improves survival.